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ABSTRACT 
LEE WADE HUTSON: The Effects of Central Interleukin-1 Signaling on Peripheral 
Immunomodulation  
(Under the direction of Donald T. Lysle) 
  
Heroin administration suppresses the production of nitric oxide (NO), which is a 
molecule active in host defense against infection and disease. Previous research in our laboratory 
has demonstrated that the immunosuppressive effects of heroin can be conditioned by repeatedly 
pairing heroin administration with a unique environmental context. Re-exposure to the 
previously drug-paired context can illicit immunosuppressive effects similar to heroin 
administration alone.  In addition, our laboratory has reported that the basolateral amygdala 
(BLA) and medial nucleus accumbens shell (mNAcS) are critical neural substrates that mediate 
this conditioned effect.  The study presented in Chapter 2 revealed the presence of interleukin-1β 
(IL-1β) immunoreactivity in the BLA and mNAcS across various time points following re-
exposure to a previously drug-paired environment; however, there were no differences in the 
level of IL-1β expression. Chapter 3 demonstrated that blockade of IL-1 signaling in the BLA, 
but not CPu or mNAcS, attenuates heroin-conditioned immunosuppression of NO production 
and inducible nitric oxide synthase (iNOS) mRNA expression in spleen tissue. Chapter 4 found 
that intra-BLA administration of various doses of IL-1β had no effect on NO production or iNOS 
mRNA expression following an immune challenge. Taken together, these findings suggest that 
 iv  
IL-1 signaling in the BLA is necessary for the expression of heroin-conditioned 
immunosuppression of NO and iNOS mRNA. In addition, these findings indicate that exogenous 
IL-1β administration into the BLA does not alter the peripheral induction of NO in blood plasma 
or iNOS mRNA expression in spleen tissue following an immune challenge. 
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CHAPTER 1 
GENERAL INTRODUCTION 
A Brief History of Opioids and Opioid Abuse 
Heroin is derived from the sap of the opium poppy plant (Papaver somniferum), which is 
a major source of opium and poppy seeds. Papaver somniferum is just one of the 250 species of 
Papaveracea family, but it is the most cultivated of the poppy plants due to its 
pharmacotherapeutic and euphoric effects. Archaeological evidence suggests opium poppy was 
being used as long ago as 5000 BCE based on the discovery of Sumerian cuneiform tablets 
containing the words for opium and Assyrian reliefs illustrating opium. Sumerians referred to 
opium poppy as hul gil, which means the “plant of joy”. Many believe the Sumerians were the 
first to cultivate opium poppy circa 3300 BCE, however, archaeological data collected from of 
opium poppy seeds discovered in Switzerland, Spain, the Netherlands, Greece, and Cyprus 
suggest that opium poppy had been cultivated and used in Western and Central Europe since 
4600-3800 BCE (Baser and Arsan, 2014). In 1903,  evidence of opium was found in ancient 
Egypt (ca 1400 BCE), where a sample was recovered from the tomb of the chief royal architect 
Kha; however, the reliability of the initially reported analyses of the contents of the tomb have 
been questioned (Bisset et al., 1994). During the prominence of the Egyptian Empire, the city of 
Thebes became so popular for its cultivation of opium poppy that Egyptian opium became 
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known as Thebic opium, which is how the alkaloid thebaine derived its name (Hagel et al., 
2007).  
References to opium use have been found among the writings of Greek authors and 
philosophers. Homer wrote of Helen, the daughter of Zeus, giving soldiers nepenthe, an opium-
based drug, to “lull all pain and anger and bring forgetfulness of every sorrow.” It has been 
suggested that opium poppy was used for various purposes, including religious rituals, pain 
relief, euthanasia, and even as a means to prevent excessive crying in children (Brownstein, 
1993). In addition, Hippocrates advocated for the medicinal use of opium poppy. He prescribed 
it as a sleep aid, for pain relief, to seal wounds and stop bleeding, and for the alleviation of a 
negative affective state (Hagel et al., 2007, Fernandez and Libby, 2011). 
By the 10
th
 century, opium had spread from Asia Minor throughout Europe and China. 
Turkey had become a major cultivator of opium by the 16
th
 century, with exports reaching India, 
China, and Indonesia (Baser and Arsan, 2014). After China banned tobacco smoking in the mid-
17
th
 century, smoking opium became the alternative. By the 18
th
 century, the British run Eastern 
India Trading Company began trading India-grown opium to China. As a result, the increase in 
opium use caused a serious public health crisis, which contributed to China’s 1729 decision to 
prohibit the sale and consumption of opium. Efforts to stop the East Indian Trading company’s 
supply from entering China led to the 1
st
 and 2
nd
 Opium Wars, which China ultimately lost. 
China was the major consumer of opium at the time, accounting for 75% of the opium produced 
in India. In fact, Hong Kong was known as the Opium State (Baser and Arsan, 2014). Due to a 
2
nd
 Opium War and increased pressure from Britain and France, China eventually began to allow 
the growth of opium poppies, and, as a result, it is estimated that 27% (i.e. 13.5 million people) 
of China’s population were opioid addicts by 1906 (Lu et al., 2008).  
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During this time, another opiate was synthesized. Morphine was isolated from opium 
sometime between 1803 and 1805 by the German scientist Friedrich Sertürner. He named this 
new drug after the god of dreams, Morpheus.  Since that time, over 40 alkaloids – which account 
for the activity of opium - have been isolated from opium. The problem of opioid addiction first 
emerged as a widespread health concern in the United States during and following the Civil War. 
Morphine was most commonly used by doctors during surgical procedures and to treat pain. It 
was also widely used during this time as treatment for general discomfort and stress. However, it 
soon became apparent that the abuse potential and hazardous consequences associated with 
morphine use were equal to those of opium. Interestingly, following the Civil War, the majority 
of opioid addicts were not former soldiers. Two-thirds of opioid addicts were women because of 
the widespread prescription of opiates for menstrual and menopausal discomfort (SAMHSA, 
2012). Due to their extensive medicinal use, efforts were made to produce a safer, more 
efficacious, nonaddicting opiate. In 1898, heroin was synthesized and believed to be a more 
potent and nonaddcitive replacement for morphine. Unfortunately, both of these claims were 
proven to be false (Brownstein, 1993). Heroin was initially introduced as a cough suppressant, 
but it soon began to be abused because of its euphoria-inducing effects. In addition, the spread of 
intravenous self-administration resulting from the advent of the hypodermic needle had a 
profound effect on opioid addiction.  
In the early 20
th
 century, the demographics of opioid abusers began to change. The arrival 
of young European immigrants led to overcrowded housing in ghettos and substandard 
neighborhoods where opiate use was common, resulting in many immigrants becoming addicted. 
As time went on, crime rates in these urban areas rose, as addicts were turning to illegal means to 
support their drug habit. Following World War II, many European immigrants relocated outside 
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of the crowded cities, which led to Hispanics and African-Americans moving into areas where 
opioid abuse was already a serious problem. As a result, many people from these groups also 
developed an addiction. Illicit opioid use and addiction-related crime continued to rise 
throughout the mid-20
th
 century. By the 1980s, it is estimated that 500,000 Americans used illicit 
opioids, and by the end of the 1990s that number nearly doubled to 898,000 (Treatment, 2005).  
In the early 20
th
 century, the U.S. government began to pass legislation aiming to curtail 
the problem of opioid abuse. For example, in 1909, the Smoking Opium Exclusion Act was 
passed, banning the smoking and possession of opium, while continuing to allow its use for 
medicinal purposes. In order to tax the manufacture and distribution of narcotics, the Harrison 
Narcotic Act was enacted in 1914, requiring federal oversight in the production, distribution, and 
prescription of opioids.  Furthermore, the Heroin Act was passed in 1924, which prohibited the 
manufacture, importation and possession of heroin, even for medicinal use. Ultimately, the 
Controlled Substance Act of 1970 was passed as a means to consolidate numerous laws 
regulating the manufacture and distribution of illicit and non-illicit drugs. 
Over the past decade, the number of heroin users in the United States has steadily risen, 
with an estimated 681,000 users in 2013 (Lipari and Hughes, 2015). One factor that may have 
contributed to this steady rise in heroin use is increased prescribing of painkillers, such as 
hydrocodone and oxycodone. Recently, tighter restrictions have been placed on the prescribing 
of painkillers, thus reducing opioid analgesic availability (Dart et al., 2015). However, the 
reduction in prescription painkiller misuse has been accompanied by increases in heroin use, 
suggesting that opioid-dependent individuals are resorting to heroin as a substitute. As a result, 
heroin use will remain a significant threat to public health for the foreseeable future (Cicero and 
Kuehn, 2014). 
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Historical Background of the Effects of Opioids on Immunity 
Long before scientific evidence of the immunomodulatory effects of opioids emerged, the 
deleterious effects of opiates on health had been observed. In the mid-16
th
 century, Fallopious, 
the professor of anatomy at Pisa, investigated the effects of opium administration in a malaria 
infected prisoner. The prisoner died following the second dose of opium, suggesting that opium 
administration expedited the progression of infectious disease. Despite this observation, it wasn’t 
until the 19
th
 century that the notion of negative health consequences associated with opioid use 
began to be accepted. In fact, it was previously believed that opium could be used to treat 
infections. However, a change in thinking began in 1821 when Thomas De Quincey published 
“Confession of an English Opium-Eater”, in which he provided an autobiographical account of 
his laudanum addiction and the impact it had on his life. In his book, he included a chapter 
discussing the “miseries of opium,” which led to a long debate about the deleterious effects of 
chronic opiate use (Rishdal et al., 1996). 
In 1866, Edmund Arnold suggested that morphine should not be used to treat diseases 
when inflammation and “constitutional irritation” have developed. In addition, Alonzo Calken 
argued against the commonly held belief that opium prolongs life, and that opium users are, in 
fact, “plagued with disease.” Furthermore, Thomas Whipham (1875) concluded that the onset of 
acute pleuropneumonia occurred more rapidly and resulted in a higher mortality rate among 
opiate addicts, suggesting that opiates contributed to the development of the disease. As evidence 
for the detrimental health consequences associated with opioid use began to grow, researchers 
began investigating these effects in animal models. For example, Coronedi (1897) demonstrated 
that sub-lethal doses of morphine increased susceptibility to infection in dogs. In the early 20
th
 
century, many others noted similar disease complications associated with opioid use in clinical 
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and experimental settings (Rishdal et al., 1996). During a time when interest in this line of 
research was waning, Hussey and Katz (1950) published a seminal study reporting various 
medical and surgical complications resulting from addiction to opiates, including skin abscesses, 
thrombophlebitis, septicima, acute bacterial endocarditis and tetanus. Additional reports were 
subsequently published also reporting a high incidence of bacterial, fungal and viral infections as 
a result of opiate use (Louria et al., 1967, Luttgens, 1949). In the 1960s, there was a significant 
rise in drug use across American and among soldiers fighting in Vietnam. Thus, drug abuse was 
thrust back into the national consciousness. Despite this increased awareness, it was not until the 
1980s and the emergence of the AIDS epidemic that the research community began to seek to 
understand the mechanisms mediating opiate abuse and increased susceptibility to infection.  
Opioids and Immunity 
The latter half of the 20
th
 century produced a wealth of research investigating the effects 
of opiates on immune function. Clinical studies have revealed abnormalities in basic immune 
parameters in heroin users, including a decrease in circulating lymphocytes, natural killer (NK) 
cell activity, cytokine production, and antibody-dependent cellular cytotoxicity (Nair et al., 1986, 
Govitrapong et al., 1998, Yardeni et al., 2008). These finding have also been extended into 
preclinical rodent models of opiate-induced immunomodulation. Morphine has been shown to 
suppress NK cell activity (Friedman et al., 2003, Weber and Pert, 1989, Yokota et al., 2004) and 
lymphocyte proliferation (Friedman et al., 2003, Bayer et al., 1990b, Bayer et al., 1990a, Gomez-
Flores and Weber, 2000, Hamra and Yaksh, 1996). In addition, opiate administration decreases 
phagocytosis (Tubaro et al., 1983, Rojavin et al., 1993, Pacifici et al., 1993) and chemotaxis 
(Grimm et al., 1998, Liu et al., 1992), which are important for pathogen clearance and 
transporting immune cells to sites of infection or injury, respectively. Furthermore, opioid 
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receptor agonists suppress nitric oxide (NO) production (Schneider and Lysle, 1998, Menzebach 
et al., 2004, Bhaskaran et al., 2007), the expression of inducible nitric oxide synthase (iNOS)  
(Lysle and How, 2000),  and expression of the proinflammatory cytokines interleukin-6 (IL-6), 
tumor necrosis factor – α (TNF-α) (Roy et al., 1998, Chao et al., 1993), and interleukin-1β (IL-
1β) (Pacifici et al., 2000). Thus, these studies suggest that opioid administration results in an 
impaired ability to defend against infectious disease (Theodorou and Haber, 2005).  
 Studies from our own laboratory have demonstrated that morphine administration in rats 
suppresses splenic lymphocyte proliferation, splenic NK cell activity, blood lymphocyte 
proliferation, and the in vitro production of the cytokines interleukin-2 (IL-2) and interferon- 
(Fecho et al., 1993a, Fecho et al., 1993b, Fecho et al., 1996b, Fecho et al., 1996a, Lysle et al., 
1993a, Saurer et al., 2006a, Saurer et al., 2006b). Importantly, we have demonstrated that heroin 
induces similar immunomodulatory effects (Fecho and Lysle, 2000, Fecho et al., 2000, Lysle and 
How, 2000, Saurer et al., 2009). Studies investigating opioid receptor involvement in the effects 
of heroin on immune status demonstrated that administration of the opioid receptor antagonist 
naltrexone attenuated lipopolysaccharide (LPS)-induced reductions of iNOS mRNA expression 
and NO production, indicating the immunosuppressive effect is mediated via the opioid receptor 
(Lysle and How, 2000). In addition, central monoamine signaling has been reported to alter 
peripheral immune parameters. Disruption of mesolimbic dopamine signaling impairs 
lymphocyte proliferation and NK cell activity (Deleplanque et al., 1994). Furthermore, 
pharmacological manipulation of dopamine in the nucleus accumbens has been shown to reduce 
splenic lymphocyte proliferation (Nistico et al., 1994). Studies from our laboratory identified the 
medial nucleus accumbens shell (mNAcS) as an important neural substrate mediating the effects 
of heroin on immune function. Intra-mNAcS administration of the D1 antagonist SCH-23390 
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blocked heroin’s immunosuppressive effects on NK cell activity, iNOS mRNA expression and 
NO production, indicating that D1 signaling in the mNAcS is an important mediator of heroin-
induced immune alterations (Saurer et al., 2009). Taken together, these findings clearly 
demonstrate that opioids alter host defense against infection. 
 
Nitric Oxide 
 In order to effectively defend against foreign invaders, the mammalian immune system 
has developed a wide range of intracellular defense mechanisms. One such mechanism of host 
defense is the production of NO. Its antimicrobial effects on a wide range of pathogens make it 
an effective defender against infections by bacteria, fungi, and parasites, viruses (James, 1995, 
Reiss and Komatsu, 1998, Kroncke et al., 1998, Bogdan et al., 2000). Studies have shown that 
NO is produced by many immune cells, particularly the macrophage, and its release results in 
several immunoprotective actions, including vasodilation, inhibition of platelet adhesion 
molecules, and mediating macrophage cytotoxicity (Suschek et al., 2004, Tuteja et al., 2004), as 
well as promoting pathogen elimination in non-NO producing bystander cells (Olekhnovitch et 
al., 2014).  
 NO is produced in a two-step oxidation of L-arginine by the three isozymes of nitric 
oxide synthases (NOS): constitutively expressed endothelial NOS and neuronal NOS, as well as 
iNOS (Cifone et al., 1995). NO is a gaseous molecule with a half-life of only 3-8 seconds in an 
aqueous solution, which presents a significant challenge when attempting to directly measure its 
production (Kelm, 1999). Alternatively, our laboratory utilizes two indirect methods of 
measuring NO production: we quantify the primary metabolites of NO, nitrate and nitrite, in 
blood plasma, as well as measure the level of iNOS expression in spleen tissue, which is an 
9 
enzyme responsible for NO production.  Activation of iNOS results in high levels of NO being 
released for extended periods of time.  Given that iNOS is not constitutively expressed, it 
requires induction via proinflammatory agents, such as LPS, IL-1β, or TNF-α. In order to induce 
iNOS expression and NO production, our laboratory utilizes LPS, which is a component of the 
outer cell wall of gram negative bacteria. LPS induces NO production and iNOS expression via 
activation of extracellular TLR4 receptors and subsequent activation of the intracellular NF-κB 
pathway. TLR4 receptor activation results in translocation of NF-κB into the nucleus and 
initiates transcription of several immunomodulatory genes, including iNOS.   
Conditioned Immunomodulation 
It was long believed that the central nervous and immune systems functioned 
independently of one another; however, this idea was challenged by Metalnikov and Chorine in 
1926 when a Pavlovian associative learning model was used to demonstrate for the first time that 
a previously neutral stimulus can acquire immune altering effects after pairing with an 
immunomodulatory drug. In this study, guinea pigs were injected with the plant extract Tapioka 
(unconditioned stimulus, US), which stimulates peripheral leucocyte production. Immediately 
following Tapioka administration, the animals’ skin was either heated or slightly slit 
(conditioned stimulus, CS). After repeated US-CS pairings, stimulation of the skin alone 
increased peripheral leucocyte production, indicating that skin stimulation had acquired immune 
altering effects. It wasn’t until 1975 that Ader and Cohen continued this line of research with 
their seminal study demonstrating conditioned immunosuppression in a model of conditioned 
taste aversion. In this study, the immunosuppressive drug cyclophosphamide (US) was 
repeatedly paired with saccharin mixed in water (CS). Upon ingesting saccharin water alone, 
animals exhibited a deficient immune response following immune challenge, indicating that 
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saccharin had acquired immune altering properties similar to those of cyclophosphamide. 
Subsequent studies conducted by Ader and colleagues further demonstrated conditioned 
immunomodulatory effects on the autoimmune disease systemic lupus erythematosus (Ader and 
Cohen, 1982), humoral immunity (Ader et al., 1982, Ader et al., 1993), and cell-mediated 
immunity (Ader and Cohen, 1992), which established psychoneuroimmunology as a new field of 
study.  
Building upon the work of Ader and Cohen, others began to investigate the neural 
circuitry involved in conditioned immunomodulation. Brain regions of interest were identified 
based on previous research that mapped out a basic neural circuit of the conditioned taste 
aversion model, which was used to model conditioned immunosuppression by pairing saccharin 
with the immunologic drug cyclosporine A. Excitotoxic lesions performed following the 
acquisition phase in the insular cortex and ventromedial hypothalamus, but not the amygdala, 
were found to prevent the expression of conditioned immunosuppression of lymphocyte 
proliferation, IL-2, and interferon-γ (Pacheco-Lopez et al., 2005). 
Interestingly, opioid-induced immunosuppression was found to be mediated by the 
central nervous system (CNS) (Shavit et al., 1986, Fecho et al., 1996a, Hoffman et al., 1995). 
According to the previously described studies demonstrating conditioned immunomodulation, 
the immunosuppressive effects of exogenous opioid administration cannot exclusively be 
attributed to acute pharmacological effects on physiology. Early research from our laboratory 
reported that the immune altering effects of opioids, including those of morphine and heroin, can 
be conditioned to environmental stimuli by pairing opioid administration with exposure to a 
distinct environmental context. As a result, a morphine-paired context (CS) can acquire immune 
altering effects. For example, following conditioning sessions during which morphine injections 
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were paired with a CS, rats exhibited significant reductions in mitogenic responsiveness of 
lymphocytes, NK cell activity, and IL-2 production when re-exposed to the CS  in a drug free 
state, demonstrating morphine-conditioned immunosuppression (Coussons et al., 1992, 
Coussons-Read et al., 1994a, Coussons-Read et al., 1994b). Moreover, our laboratory has shown 
that a heroin-associated context elicits a significant reduction of LPS-induced iNOS expression 
(Lysle and Ijames, 2002, Szczytkowski and Lysle, 2007, Szczytkowski and Lysle, 2008, 
Szczytkowski and Lysle, 2010, Szczytkowski et al., 2011, Szczytkowski et al., 2013, Hutson et 
al., 2014).  
Studies investigating the role of neurotransmitters in conditioned immunomodulation 
found that antagonism of dopamine and glutamate receptors block this effect (Hsueh et al., 1999, 
Kuo et al., 2001), which guided studies in our laboratory investigating the contributions of 
specific neurotransmitters to morphine- and heroin-conditioned immunosuppression. The results 
of the studies demonstrated that dopamine receptor activity is necessary for the expression of 
morphine-conditioned immune alterations, as administration of a D1 receptor antagonist prior to 
re-exposure to the conditioned stimulus prevented the suppression of NK cell activity (Saurer et 
al., 2008a). Our laboratory also demonstrated similar immunomodulatory effects with heroin 
(Fecho and Lysle, 2000, Lysle and Ijames, 2002, Szczytkowski and Lysle, 2010). 
Emerging evidence suggests that a limbic neural circuit mediates the expression of 
heroin-conditioned immune alterations.  In support of this, either GABA agonist-induced neural 
inactivation of, or dopamine D1 receptor antagonism in, the basolateral amygdala (BLA) blocks 
heroin-conditioned immunosuppression (Szczytkowski and Lysle, 2008, Szczytkowski and 
Lysle, 2010). Moreover, unilateral dopamine D1 receptor antagonism in the BLA coupled with 
contralateral N-methyl-D-aspartate (NMDA) glutamate receptor antagonism in the mNAcS 
12 
significantly attenuates the expression of heroin-conditioned immunosuppression. In contrast, 
ipsilateral manipulation of the same brain regions fails to disrupt heroin-conditioned 
immunomodulation (Szczytkowski et al., 2011).  These findings suggest that activation of BLA 
D1 receptors is necessary for intrahemispheric interactions between the BLA and the mNAc in 
the control of heroin-conditioned immune alterations.  Furthermore, inactivation of the anterior, 
but not posterior, ventral tegmental area (VTA) attenuated heroin-conditioned 
immunosuppression of NO production in blood plasma, as well as the expression of iNOS, IL-6 
and TNF-α in spleen tissue (Hutson et al., 2014). Taken together, these findings suggest heroin-
conditioned immunomodulation is mediated by a mesolimbic circuit consisting of the anterior 
VTA, BLA, and mNAcS. 
Centrally Active Interleukin-1 
While our efforts to map the neural circuitry mediating heroin-conditioned 
immunosuppression have been informative, the cellular mechanisms contributing to this effect 
have yet to be thoroughly investigated. In recent history, there has been a conceptual shift 
regarding the functional significance of cytokines in the brain.  Once viewed primarily as 
immune molecules that mediate inflammatory events during infection, cytokines are now 
recognized to be critical mediators of neuronal communication more akin to neurotransmitters 
and neuropeptides. Therefore, neuroimmune signaling within the brain may be integral to the 
impaired immune responses observed among drug abusers and animal models of drug abuse.  
One mechanism of interest is the cytokine, interleukin-1 (IL-1). IL-1 is a critical 
proinflammatory cytokine active in many biological functions, but it is primarily known for its 
involvement in host defense against infection and disease. As part of the acute phase response of 
the innate immune system, IL-1 is immediately released from resident immune cells upon 
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detection of foreign pathogens, whereupon it works to limit the spread of infection and kill off 
foreign invaders. The IL-1 family is comprised of various subtypes functioning as agonists, 
antagonists or anti-inflammatory cytokines. Proinflammatory cytokines were often thought to be 
exclusively synthesized and secreted via immune cells of the peripheral nervous system, but it 
has been demonstrated that activated microglia and astrocytes are the primary source of 
cytokines in the brain (Rothwell et al., 1996, Hanisch, 2002, Davies et al., 1999, Toda et al., 
2002).  
The most widely studied cytokine is IL-1β. Due to its neurotoxic effects at high levels, 
IL-1β is expressed at a low concentration under normal conditions. However, upon release from 
microglia, IL-1β can further induce IL-1β release in an autocrine/paracrine fashion by binding to 
membrane bound IL-1 type 1 receptors (IL-1R1) (Rothwell and Luheshi, 2000, Toda et al., 2002, 
McMahan et al., 1991). Interestingly, dysfunctional IL-1 signaling has been observed in many 
pathological disease states, such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s 
disease, in which IL-1β expression is exaggerated, thus glial activation and subsequent release of 
IL-1β could be important mediators of neurodegenerative diseases. Given its detrimental 
neuroinflammatory effects, it is clear that IL-1β signaling must be tightly regulated. To 
accomplish this, there are two primary biological mechanisms that regulate IL-1 activity: the 
endogenous antagonist interleukin-1 receptor antagonist (IL-1Ra) and the decoy receptor type 2 
IL-1 (IL-1R2).  In addition, anti-inflammatory cytokines such as IL-6 and IL-10 exist in part to 
further modulate IL-1 signaling. Further indicating the importance of controlling IL-1 signaling, 
IL-1Ra has a higher affinity for IL-1R1 than IL-1β, and IL-1β has a higher affinity for IL-1R2 
(Dinarello, 2009). Taken together, these diverse regulatory mechanisms act in concert to main 
IL-1 homeostasis and preserve normal biologic function. 
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Central IL-1 signaling has been shown to be particularly important in neural plasticity, 
learning, and memory. For example, IL-1β expression in the rat hippocampus is increased 
following long-term potentiation (LTP) induction, and this effect is disrupted by administration 
of the IL-1R1 antagonist, IL-1Ra, following LTP induction (Schneider et al., 1998, Cunningham 
et al., 1996, Vereker et al., 2000a). Furthermore, IL-1R1 knockout mice display memory 
impairments and disrupted induction of LTP (Koo and Duman, 2009). Similarly, animals treated 
in two separate studies with IL-1Ra following repeated foot shock and exposure to a spatial 
learning task displayed impaired fear conditioning and performance in the Morris water maze, 
respectively (Pugh et al., 2001, Yirmiya et al., 2002). Finally, our laboratory has demonstrated 
that inhibition of IL-1β expression in the dorsal hippocampus attenuates the immunosuppressive 
effects of a previously heroin-paired context. Thus, there is substantial evidence for the role of 
IL-1 signaling in learning and memory. However, the effects of IL-1β expression seem to follow 
an inverted U-shaped pattern in regards to its role in learning and memory. It has been reported 
that peripheral induction of cytokine expression via central administration of IL-1β or systemic 
administration of endotoxin increases central cytokine expression, which can result in impaired 
cognitive performance (Eriksson et al., 2000).  In addition, peripheral cytokines are able to 
induce cytokine release in glial cells via blood-borne and neuroimmune pathways (Nguyen et al., 
1998, Pugh et al., 1998), indicating communication between the immune system and CNS. 
Moreover, progressive increase in IL-1β levels and microglial activation have been observed as a 
result of aging (Roubenoff et al., 1998, Wilson et al., 2002), which is often correlated with 
cognitive and memory impairments. Taken together, these findings indicate that exaggerated IL-
1β expression is detrimental to cognitive performance and normal behaviors. 
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Based on the fact that both inhibition and overstimulation of IL-1 receptors produce 
various cognitive-behavioral deficits, it stands to reason that a physiologically active level of IL-
1 signaling is involved in the facilitation of normal biological function. However, determining 
the range of IL-1β expression that facilitates homeostatic function is challenging because it likely 
varies depending on the physiological action. Despite this challenge, Yirmiya and colleagues 
(2002) demonstrated that intracerebroventricular (i.c.v.) administration of a low dose of IL-1β 
immediately following passive avoidance training resulted in enhanced memory 5-8 days later. 
Similar memory enhancing effects were also observed when i.c.v. IL-1β was administered prior 
to passive avoidance training, as well as before memory tests (Song et al., 2003). Furthermore, 
IL-1β has been found to facilitate spatial and contextual fear memories. For example, IL-1β 
administration enhanced the acquisition of spatial memory in a Morris water maze task 
(Gibertini, 1998). Moreover, administration of a low dose of IL-1β immediately following 
contextual fear conditioning improved fear learning (Goshen et al., 2007). In summary, these 
studies indicate that IL-1 is a tightly regulated and important neuromodulator of many 
physiological and behavioral processes. 
 
Goals of Dissertation 
The studies presented in this dissertation aimed to elucidate the peripheral 
immunomodulatory role of central IL-1 signaling in heroin-conditioned immunosuppression. In 
addition, I sought to determine the effects of central administration of IL-1β on peripheral 
immune function. Studies conducted in our laboratory have uncovered a neural circuit mediating 
heroin-conditioned immunosuppression. Thus, the current studies sought to identify a novel 
mechanism within this circuit mediating the conditioned effects of heroin on peripheral immune 
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parameters. Chapter 2 examines the effect of re-exposure to a heroin-paired context on IL-1β 
expression in the brain. Chapter 3 investigates the role of IL-1 signaling in the BLA, caudate 
putamen (CPu), and mNAcS in the expression of heroin-conditioned immunosuppression. 
Finally, Chapter 4 tested the effect of intra-BLA IL-1β administration on peripheral immune 
function. Together, these studies provided insights into the role of neuroimmune signaling in the 
modulation of peripheral immune function. 
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CHAPTER 2 
TIME COURSE OF INTERLEUKIN-1β EXPRESSION IN THE BASOLATERAL 
AMYGDALA AND MEDIAL NUCLEUS ACCUMBENS SHELL FOLLOWING RE-
EXPOSURE TO A PREVIOUSLY HEROIN-PAIRED CONTEXT 
Introduction 
A high incidence of infection has long been observed among opiate users (Luttgens, 
1949, Hussey and Katz, 1950, Bussiere et al., 1993, Friedman and Eisenstein, 2004). While this 
was commonly thought to be due to non-sterile intravenous drug practices, such as needle 
sharing, it has been demonstrated that opiates directly alter the ability of the immune system to 
eliminate infection. Clinical studies have revealed abnormalities in many defensive immune 
parameters among heroin users, including decreased circulating lymphocytes, NK cell activity, 
cytokine production, and antibody-dependent cellular cytotoxicity (Nair et al., 1986, 
Govitrapong et al., 1998, Yardeni et al., 2008). In addition, our laboratory has found similar 
opioid-induced immune alterations in animals. For example, animals treated with morphine, 
which is a major metabolite of heroin, exhibited decreased splenic lymphocyte proliferation, 
splenic NK cell activity, blood lymphocyte proliferation, and proinflammatory cytokine 
production (Fecho et al., 1993a, Fecho et al., 1993b, Fecho et al., 1996a, Fecho et al., 1996b, 
Lysle et al., 1993b, Saurer et al., 2006a, Saurer et al., 2006b).  
Interestingly, the immunosuppressive effects of opiates have been shown to be 
conditioned to environmental stimuli. Our laboratory has demonstrated that repeatedly pairing 
morphine or heroin with a unique environmental context causes the previously neutral context to 
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elicit an immunosuppressive response when an animal is re-exposed to that context in a 
drug free state (Coussons et al., 1992, Coussons-Read et al., 1994a, Coussons-Read et al., 1994b, 
Lysle and Ijames, 2002, Szczytkowski and Lysle, 2007). Recently, we identified a mesolimbic 
neural circuit that mediates these conditioned immunosuppressive effects. Investigations in our 
laboratory have shown that the functional integrity of the BLA, mNAcS and VTA is necessary 
for the expression of heroin-conditioned immunomodulation (Hutson et al., 2014, Szczytkowski 
and Lysle, 2008, Szczytkowski and Lysle, 2010, Szczytkowski et al., 2011, Saurer et al., 2008a). 
Despite the insights gained from these studies, there is still little known about the mechanisms 
mediating heroin-conditioned immunosuppression within these brain regions. 
One potential mechanism is IL-1, which is a potent proinflammatory cytokine that is an 
essential component of the innate immune response to infection and injury.  Induction of IL-1 in 
the peripheral nervous system in response to infection leads to production of other 
proinflammatory cytokines in order to rid the body of foreign pathogens (Maier et al., 1998, 
Quan et al., 1999, Konsman et al., 2000). Interestingly, IL-1 synthesis and secretion is not 
limited to peripheral immune cells. In fact, IL-1 has been shown to be produced and released by 
glia within the CNS (Rothwell et al., 1996, Hanisch, 2002).  
Of particular interest to the current studies, the BLA contains a high density of IL-1 
receptors (Konsman et al., 2000, Yabuuchi et al., 1994a). Over the past 20 years, evidence has 
emerged in support of IL-1 serving as a neuromodulator in the brain. For example, Yu and 
Shinnick-Gallagher (1994) demonstrated that i.c.v. IL-1β administration modulates neuronal 
firing in the BLA. In addition, studies have demonstrated that both blockade of IL-1 receptors 
and inhibition of IL-1 synthesis prevent IL-1-induced memory impairments (Pugh et al., 1998, 
Pugh et al., 1999, Gemma et al., 2005). Furthermore, IL-1β administration directly into the 
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dorsal hippocampus has been shown to impair memory (Barrientos et al., 2002) and inhibit LTP 
(Cunningham et al., 1996, Vereker et al., 2000a, Vereker et al., 2000b, Murray and Lynch, 
1998). While it is not surprising that complete inhibition or gross over expression of a potential 
neuromodulator is detrimental to biological function, it is, however, interesting that central 
administration of low doses of IL-1β have been shown to facilitate learning in various learning 
and memory paradigms (Yirmiya et al., 2002, Song et al., 2003, Goshen et al., 2007). Based on 
these findings, it is clear that IL-1 is an important mediator of learning and memory.  To date, the 
overwhelming majority of published research investigating the role of central IL-1 in learning 
and memory has focused on the hippocampus. Therefore, there is a need to explore the 
contribution of IL-1 in neural processing within other brain regions, such as the BLA and 
mNAcS, as these brain regions have been reported to be important for the expression of 
conditioned learning. 
Recently, our laboratory has worked to identify the neural substrates that mediate heroin-
conditioned immunosuppression. As previously mentioned,  we have determined that activation 
of the VTA, BLA, and mNAcS are necessary for the expression of heroin-conditioned 
immunosuppression, further supporting research indicating that these brain regions are important 
for the expression of associative learning (See et al., 2003) Given the importance of IL-1 
signaling in learning and memory, the current study sought to investigate the importance of IL-1 
signaling in our model of heroin-conditioned immunomodulation. The goal of the study 
described in this chapter was to determine the time course of IL-1β expression in the BLA and 
mNAcS following re-exposure to the previously heroin-paired environment using 
immunohistochemical techniques to assess IL-1β immunoreactivity. 
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Materials and Methods 
Animals 
Male Lewis rats, weighing 225–250 g, were purchased from Charles River Laboratories 
(Raleigh, NC, USA). Upon arrival, animals were housed individually in plastic cages in a colony 
room with a reversed light-dark (12-h) cycle maintained through artificial illumination. Animals 
were allowed access to food and water ad libitum throughout the experiment except for the time 
spent in the conditioning chambers when food and water were not available. All animals were 
given a 2-week habituation period before the start of experimental manipulations and were 
handled regularly during this time. All procedures described were approved by the IACUC of the 
University of North Carolina at Chapel Hill and conformed to NIH guidelines on the care and 
use of laboratory animals. 
Drug Administration 
Heroin (diacetylmorphine) was obtained from NIDA (Bethesda, MD, USA) and 
dissolved in 0.9% sterile saline. Heroin was administered subcutaneously at a dose of 1 mg/kg. 
This dose was selected based on prior experiments in our laboratory showing that it induces 
conditioning and alters LPS-induced iNOS expression in spleen tissue and NO production in 
blood plasma (Lysle and How, 2000, Lysle and Ijames, 2002, Szczytkowski and Lysle, 2007). 
Conditioning Procedure 
All animals received five conditioning sessions in standard conditioning chambers 
(BRS/LVE, Laurel, MD, USA).  Chambers were fitted with a metal grid floor design and cedar 
bedding to create an environment distinct from that of the home cage and to provide both 
olfactory and tactile cues for conditioning. Artificial noise machines were used to minimize 
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background noise. All conditioning took place during the dark phase of the light cycle in a room 
separate from the animal colony and the conditioning chambers were kept dark to minimize 
effects on circadian rhythms. On each conditioning day, a subcutaneous injection of heroin 
(1 mg/kg) was administered immediately prior to placement into the chamber for 60-min. 
Training sessions were separated by 48 h.  
Test of Heroin-Conditioned Immunomodulation 
Six days after the final conditioning session, rats were sacrificed following a 0, 15, 60 or 
120 min (120 min animals were re-exposed for 60 minutes then returned to home cage for 60 
min) exposure to the heroin-paired context. 
Immunohistochemistry 
Rats were overdosed with anesthetic (Ketamine/xylazine 100mg/kg; i.p.) and transcardially 
perfused with 0.1M phosphate buffered saline (PBS, pH = 7.4) followed by 4% paraformaldehyde 
in PBS. Brains were extracted, postfixed in paraformaldehyde for 24 hours and sectioned coronally 
at 40μm using a vibrating microtome (Leica VT1000S; Wetzlar, Germany). Sections were collected 
in a 1:12 series and stored in cryoprotectant at -20˚C until processing so that every twelfth section 
was stained for IL-1β immunoreactivity. Tissue was washed in 0.01M TBS (pH=7.4) and pre-
incubated for 1 hr at room temperature in 3% goat serum block. Following additional washes, 
sections were blocked for nonspecific binding (TBS, 0.1% triton X-100, and 3% goat serum) for 1 
hr, and then incubated overnight in rabbit anti-IL-1β (1:1000, Abcam; Cambridge, MA) primary 
antibody at 4˚C. The next day, tissue underwent several washes in 0.01M TBS followed by a wash 
with 3% H2O2 in TBS to quench endogenous peroxidases. Sections were again blocked for 
nonspecific binding and incubated in biotinylated goat anti-rabbit secondary antibody (Vector 
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Laboratories, Burlingame, CA) and washed in TBS. Staining of antibody binding was achieved with 
an avidin-biotin-peroxidase complex (ABC Elite Kit, Vector Laboratories) and chromagen, nickel-
enhanced 3,3’-diaminobenzidine tetrahydrochloride (DAB; Polysciences, Warrington, PA) to detect 
IL-1β binding. Sections were dried then mounted to glass slides and coverslipped with 
SHUR/Mount
™ 
(Triangle Biomedical Sciences; Durham, NC). 
Quantification and Statistical Analysis 
Slides were coded to ensure experimenter blindness to treatment to conditions for 
quantification. Images were taken of the regions of interest at 20x magnification with a digital 
camera (Roper Scientific) mounted on an optical microscope. IL-1β immunoreactivity was 
determined by optical density using an autothreshold in the ImageJ software, with percent area of 
staining reported as percent control. A one-way ANOVA was used to determine differences in 
percent area of total IL-1β staining across all groups in the BLA and mNAcS. All analyses were 
performed with the alpha level of significance set at p < 0.05. 
 
Results 
IL-1β immunoreactivity in the basolateral amygdala and medial nucleus accumbens shell 
following re-exposure to a heroin-paired context 
As you can see in Figure 2.1, there are IL-1β immunoreactive cells in the BLA at all time 
points (A, 0 min; B, 15 min; C, 60 min; D, 120 min); however, ANOVA revealed no differences 
in IL-1β immunoreactivity (E)  [F(3,16) = 0.18, p > 0.05] across all groups, indicating that re-
exposure to the previously heroin-paired environment does not alter IL-1β immunoreactivity in a 
time-dependent manner. Similarly, Figure 2.2 confirms the presence of IL-1β immunoreactivity 
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in the mNAcS at all time points (A, 0 min; B, 15 min; C, 60 min; D, 120 min). Furthermore, 
ANOVA revealed no differences in IL-1β immunoreactivity (E) [F(3,16) = 1.48, p > 0.05]. 
   
   
 
 
Figure 2.1: IL-1β immunoreactivity in the BLA following 5 days of heroin conditioning. 
Animals were re-exposed to the CS for (A) 0 minutes, (B) 15 minutes, (C) 60 minutes, or (D) 60 
minutes plus 60 minutes in home cage (120 minutes). Representative photomicrographs show 
similar IL-1β immunoreactivity at all time points (A-D) and no statistically significant 
differences across groups (E). All data presented as mean ± SEM. 
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Figure 2.2: IL-1β immunoreactivity in the mNAcS following 5 days of heroin conditioning. 
Animals were re-exposed to the CS for (A) 0 minutes, (B) 15 minutes, (C) 60 minutes, or (D) 60 
minutes plus 60 minutes in home cage (120 minutes). Representative photomicrographs show 
similar IL-1β immunoreactivity at all time points (A-D) and no statistically significant 
differences across groups (E). All data presented as mean ± SEM.  
 
Discussion 
The findings presented in the current chapter demonstrate that IL-1β is expressed in the 
BLA and mNAcS prior to and during re-exposure to a previously heroin-paired context. The 
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presence of BLA IL-1β expression is supported by previous studies indicating dense IL-1 
receptor expression in the BLA (Konsman et al., 2000, Yabuuchi et al., 1994b), which suggests 
that IL-1β signaling may be important for BLA neural processing. I hypothesized that IL-1β 
would be elevated as a result of re-exposure to a heroin-paired context based on previous 
research indicating that IL-1β plays an important role in associative learning (Goshen et al., 
2007, Yirmiya et al., 2002).  
The primary source of IL-1β synthesis and release is believed to be glial cells. 
Interestingly, increased microglial activation has been observed following re-exposure to a 
morphine-paired context in a model of CPP (Schwarz et al., 2011). Therefore, it is possible that 
re-exposure to a heroin-paired context stimulates microglial activation and results in subsequent 
increased IL-1β expression. However, based on our findings, it does not appear that BLA or 
mNAcS IL-1β levels were increased following re-exposure to the heroin-paired context. One 
possibility is that heroin administration induced persistent IL-1β expression, as it is well 
documented that opiate administration activates microglial cells (Milligan and Watkins, 2009). 
For example, increases in microglial activation markers have been observed following chronic 
codeine (Johnson et al., 2014) and morphine administration (Raghavendra et al., 2002, 
Hutchinson et al., 2009, Song and Zhao, 2001). Thus, it is possible that this activated state could 
persist long after morphine exposure. In fact, Zhang and colleagues (2012) found microglial 
activation five days following morphine administration in a model CPP, indicating that 
microglial activation on test day in the studies discussed in this dissertation is possible, as brain 
tissue was collected at a similar time point. Under normal physiologic conditions, IL-1β is 
expressed at low levels and often hard to detect. Thus, the high levels of IL-1β immunoreactivity 
observed in the current study could be due to sustained increases in IL-1β expression as a result 
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of persistent microglia activity following heroin conditioning. There is also evidence that 
conditioning in the absence of drug induces IL-1β release. Increases in IL-1β mRNA expression 
have been observed at 24 hours (Goshen et al., 2007) and up to 72 hours following fear 
conditioning (Jones et al., 2015), suggesting that IL-1β may play a role in memory formation. 
Indeed, inhibition of IL-1 receptor signaling following fear conditioning has resulted in impaired 
memory upon testing (Jones et al., 2015). Collectively, these data suggest that heroin-induced 
associative learning could induce IL-1β expression well beyond exposure to the CS. In addition, 
opioid administration has been shown to increase the expression of IL-1β in CNS endothelial 
cells and spinal cord tissue (Wang et al., 2012, Liu et al., 2011b, Liu et al., 2011a, Fukagawa et 
al., 2013); however, the time course of IL-1β expression following opioid administration has 
proven to be complex. Some studies did not observe increases in IL-1β mRNA expression 
beyond 2 hours following opiate administration (Wang et al., 2012), whereas others have 
reported increases occurring 3-7days following the cessation of opioid administration (Berta et 
al., 2013). These discrepancies are likely due to varying doses, schedules of drug administration, 
time points at which IL-1β was measured, as well as tissues analyzed. Nevertheless, it is 
plausible that heroin administration produced the high levels of IL-1β expression observed in the 
current study.  
Taken together, these data indicate dense IL-1β expression in the BLA and mNAcS 
following heroin conditioning; however, additional control studies are needed to determine if 
repeated administration of heroin and/or exposure to our conditioned stimulus could result in 
long-term microglial activity and IL-1β release compared to naïve animals. These findings 
suggest that IL-1 signaling may play an important role in heroin-conditioned immune alterations, 
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thus, Chapter 3 continues to explore the role IL-1 in the BLA and mNAcS in the expression of 
heroin-conditioned immunosuppression. 
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CHAPTER 3 
THE ROLE OF INTERLEUKIN-1 SIGNALING IN THE EXPERSSION HEROIN-
CONDITONED IMMUNOMODULATION 
Introduction 
The results presented in Chapter 2 demonstrate that IL-1β immunoreactivity is present in 
the BLA and mNAcS of animals that were re-exposed to the heroin-paired CS and in animals 
that were not re-exposed to the CS.  Based on the presence of IL-1β in these brain regions 
following heroin conditioning, the goals of the studies conducted in Chapter 3 were to determine 
whether IL-1 signaling within the BLA and mNAcS is necessary for the expression of heroin-
conditioned immunomodulation.   
It is well established that the BLA is important mediator of associative learning. In 1956, 
Weisenkrantz observed a marked decrease of fear responses to previously aversive stimuli in 
amygdala lesioned monkeys. More recently, studies have revealed that the functional integrity of 
the BLA is required for associative learning. For example, lesioning the BLA has been shown to 
impair classical eye blink conditioning (Blankenship et al., 2005). In addition, inactivation of the 
BLA via GABAergic stimulation prevents the development of fear conditioning (Muller et al., 
1997). The BLA has also been reported to be critical in models of drug-induced conditioning, as 
inactivation of the BLA has been shown to prevent the reinstatement of heroin-CPP (Cummins et 
al., 2014). Similarly, disruption of BLA signaling prevents context-induced reinstatement of 
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heroin-(Fuchs and See, 2002) and cocaine-seeking behavior (Meil and See, 1997, Grimm 
and See, 2000, Kruzich and See, 2001, See et al., 2001).  
Recently, our laboratory demonstrated the importance of the BLA and mNAcS in heroin-
conditioned immunomodulation. Inactivation of the BLA with the GABAA/B agonist cocktail 
muscimol/baclofen attenuated the immunosuppressive effect of the heron-paired context on 
several proinflammatory mediators (Szczytkowski and Lysle, 2008). Similarly, antagonism of D1 
receptors in the BLA (Szczytkowski and Lysle, 2010) and mNAcS (Saurer et al., 2008b) prior to 
re-exposure to a previously heroin-paired context significantly attenuated the expression of 
proinflammatory mediators and NK cell activity, respectively. Furthermore, activation of 
NMDA/AMPA glutamate receptors in the mNAcS was found to be necessary for the expression 
of these conditioned effects (Szczytkowski et al., 2011). Taken together, these studies 
demonstrate that the BLA and mNAcS are important neural substrates mediating the expression 
of heroin’s conditioned effects on immune function.  
As previously discussed in Chapter 2, IL-1 signaling is a critical mediator of neural 
plasticity, learning and memory, as disruption of IL-1 signaling has been shown to impair fear 
conditioning, spatial memory and LTP. In addition, a recent study from our laboratory 
demonstrated that IL-1β expression mediates conditioned immunomodulation.  
Genetic inhibition of IL-1β expression in the dorsal hippocampus prior to re-exposure to a 
previously heroin-paired context attenuated heroin-conditioned immunosuppression of iNOS 
expression and NO production. (Szczytkowski et al., 2013). Given the level of IL-1β 
immunoreactivity found in the BLA and mNAcS and the importance of these brain regions in 
heroin-conditioned immunosuppression, it’s possible that IL-1could mediate these effects. 
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The studies conducted in this chapter aimed to determine the role of IL-1 signaling in the 
BLA and mNAcS in the expression of heroin-conditioned immunomodulation. Rats received five 
conditioning sessions, with each session separated by 48-hrs, where 1 mg/kg heroin was 
administered immediately prior to placement in to a distinct context. At least six days following 
the final conditioning session, animals received bilateral microinfusions of saline vehicle or IL-
1Ra into the BLA, CPu, or mNAcS and then returned to their home cage or re-exposed to the 
previously heroin-paired context for 60 minutes. Animals were then administered a subcutaneous 
injection of LPS to induce an immune response. Six hours later animals were sacrificed and 
brain, blood plasma and spleen tissue were collected from each subject. Data collected from 
these studies indicate that IL-1 signaling in the BLA, but not CPu or mNAcS, is important for the 
expression of heroin-conditioned immunosuppression. This is the first time IL-1 signaling in the 
BLA has been shown to mediate any form of associative learning, including conditioned 
immunosuppression. 
Materials and Methods 
Animals 
Male Lewis rats, weighing 225–250 g, were purchased from Charles River Laboratories 
(Raleigh, NC, USA). Upon arrival, animals were housed individually in plastic cages in a colony 
room with a reversed light-dark (12-h) cycle maintained through artificial illumination. Animals 
were allowed access to food and water ad libitum throughout the experiment except for the time 
spent in the conditioning chambers when food and water were not available. All animals were 
given a 2-week habituation period before the start of experimental manipulations and were 
handled regularly during this time. All procedures described were approved by the IACUC of the 
31 
University of North Carolina at Chapel Hill and conformed to NIH guidelines on the care and 
use of laboratory animals. 
Drug Administration 
Heroin (diacetylmorphine) was obtained from NIDA (Bethesda, MD, USA) and 
dissolved in 0.9% sterile saline. Heroin was administered subcutaneously at a dose of 1 mg/kg. 
This dose was selected based on prior experiments in our laboratory showing that it induces 
conditioning and alters LPS-induced iNOS and TNF-α mRNA expression in spleen tissue (Lysle 
and How, 2000, Lysle and Ijames, 2002, Szczytkowski and Lysle, 2007). 
Surgical Procedures 
Animals were fully anesthetized with 0.35 mL intramuscular injections of 1:1 (vol:vol) 
ketamine hydrochloride (100 mg/mL) mixed with xylazine (20 mg/mL) and placed into the 
stereotaxic apparatus. Animals were implanted bilaterally with 26-gauge guide cannulae (Plastics 
One, Roanoke, VA, USA). The cannulae were directed towards BLA (AP −2.5, ML ± 5.0, DV 
−6.6), mNAcS (AP −1.7, ML ± 0.8, DV −5.4), or CPu (AP −2.5, ML ± 5.0, DV −4.0). 
Coordinates are mm relative to bregma. Animals were given a 2-week post-surgical recovery 
period before the start of conditioning trials.  
Conditioning Procedure 
All animals received five conditioning sessions in standard conditioning chambers 
(BRS/LVE, Laurel, MD, USA).  Chambers were fitted with a metal grid floor design and cedar 
bedding to create an environment distinct from that of the home cage and to provide both 
olfactory and tactile cues for conditioning. Artificial noise machines were used to minimize 
background noise. All conditioning took place during the dark phase of the light cycle in a room 
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separate from the animal colony and the conditioning chambers were kept dark to minimize 
effects on circadian rhythms. On each conditioning day, a subcutaneous injection of heroin 
(1 mg/kg) was administered immediately prior to placement into the chamber for 60-min. 
Training sessions were separated by 48 h.  
Test of Heroin-Conditioned Immunomodulation 
Six days following the final conditioning session, animals received bilateral 
microinfusions of saline vehicle (0.5  μl per hemisphere) or interleukin-1 receptor antagonist (IL-
1Ra) (1.25 μg per 0.5 μl per hemisphere) into the BLA or mNAcS. Injectors extended 2 mm 
beyond the tip of the guide cannula. Injections were delivered over 2 min, and the injectors were 
left in place for 1 min after the injection to allow for proper diffusion of fluid away from the 
infusion site. Thirty minutes later, the rats were re-exposed to the previously heroin-paired 
conditioning chamber or returned to their home cage for 60 min.  Heroin was not administered 
on test day in order to isolate the effect of the CS on immune responses. After the 60-min time 
period, all rats received a subcutaneous injection of LPS (1,000 μg/kg) and were immediately 
returned to their home cages. LPS, a component of the cell wall of Gram negative bacteria, was 
used to induce iNOS expression and NO production. Six hours following LPS administration, all 
animals were euthanized.  The 6-h time point was selected based on previous research in our 
laboratory showing maximal iNOS induction 6 h following LPS administration (Lysle and How, 
2000). 
Histology 
Samples of spleen and blood were collected for analysis. Spleen samples were either 
stored in an Ambion® RNA Later solution or Roche complete protease inhibitor cocktail 
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solution. To confirm proper cannula placement, Alcian blue dye was infused via the cannula. 
Brains were then extracted and flash frozen and at − 80 °C until further analysis. Coronal 
sections (40 μm) were taken and stained with cresyl violet for verification of cannula placement. 
The data of animals with cannula placement outside of the targeted region were removed from 
subsequent data analyses.  
                                                                                                                           
                                                            
Figure 3.1: Illustration of verified cannula placement. Black dots represent the ventral most 
point of injector in the (A) BLA, (B) CPu, and (C) mNAcS. 
Real-Time RT-PCR 
Tissue was processed by the UNC Animal Clinical Chemistry and Gene Expression 
Laboratories according to protocols previously reported (Kim et al, 2002). In brief, spleen tissue 
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(50-100 mg) was homogenized in RNA lysis buffer (PE Biosystems, Foster City, CA) with 
Ca2and Mg2- free PB using a Fast Prep 120 mixer (QBIOgene, Vista, CA). RNA isolations were 
purified using the ABI Prism 6700 automated nucleic acid workstation (PE Biosystems) 
according to the manufacturer’s protocol. Real-time RT-PCR amplifications were performed in 
the ABI Prism 7700 sequence detector (PE Biosystems) in a total volume of 30 μl (10 μl RNA 
plus 20 μl reaction mixture). RT-PCR amplification was performed in duplicate: 30 min at 48°C 
for the RT reaction and 10 min at 94°C followed by 40 temperature cycles (15 s at 94°C and 1 
min at 60°C). Copy numbers were measured using the Sequence Detector Software in the ABI 
Prism 770 Sequence Detector System. Signal intensity was normalized to 18S as an endogenous 
control. The nucleotide sequences of the PCR primers and fluorogenic probes used for the iNOS 
and 18S genes were as follows: iNOS forward: 5’-AGCGGC TCC ATGACTCTC A-3’, reverse:   
5’-TGC CTGCACCCAAACACCAA-3’, probe: 5’-FTCATGCGGCCTCCTTTGAGCCCTCQ-
3’; 18S: forward: 5’-AGAAACGGCTACCACATCCA-3’, reverse: 5’-
CTCGAAAGAGTCCTGTATTGT-3’, probe: 5’-FAGGCAGCAGGCGCGCAAATTACQ. 
Nitrite/Nitrate Assay  
The nitrite/nitrate concentration in plasma samples was assessed using the Greiss reagent 
assay described previously (Szczytkowski and Lysle, 2007). Briefly, 6 μl of plasma was diluted 
in 44 μl of dH2O, and the sample was incubated in the dark for 90 min with 10 μl of nitrate 
reductase (1.0 U/ml), 20 μl of 0.31M phosphate buffer (pH 7.5), 10 μl of 0.86mM NADPH 
(Sigma), and 10 μl of 0.11mM flavin adenine dinucleotide in individual wells of a 96-well plate. 
Next, 200 ml of Greiss reagent, consisting of a 1:1 (v/v) solution 1% sulfanilamide in 5.0% 
phosphoric acid and 0.1% N-(1-napthyl) ethyl-enedamine dihydrochloride in distilled water, was 
added to the samples. The color was allowed to develop for 10 min at room temperature, after 
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which, the absorbance was determined using a spectrophotometer set at 550 nm. All reactions 
were carried out in triplicate. The total micromolar concentration of nitrite was determined for 
each sample based on a standard curve. Recovery of nitrate is greater than 95% using this assay. 
Statistical Analysis 
Two-way analysis of variance was performed on all data sets. For all analyses, planned 
comparisons were performed in accordance with a priori hypotheses that IL-1Ra would attenuate 
the effect of the immunosuppressive effect of the CS on iNOS expression and NO production. 
All analyses were performed with the alpha level of significance set at p < 0.05. 
Results 
Effects of basolateral amygdala IL-1 antagonism on heroin-conditioned 
immunomodulaiton 
Experiment 1 assessed the role of IL-1 signaling in the BLA in the expression of heroin-
conditioned peripheral immune alterations. Figure 3.2a shows the effect of intra-BLA IL-1 
antagonism on LPS-induced iNOS mRNA expression. ANOVA revealed a nearly significant 
context by treatment interaction in the BLA [F(2, 16) = 4.21, p = .057]. In addition, ANOVA 
revealed a significant main effect of re-exposure to the CS [F(1, 16) = 8.37, p < .05] on iNOS 
mRNA expression, demonstrating that re-exposure to the CS resulted in the suppression of iNOS 
and NO. Planned comparisons revealed that saline-treated rats exposed to the heroin-paired 
context exhibited a reduction in iNOS expression compared to animals placed in home cages (p 
< 0.005), indicating that heroin-conditioned immunosuppression did occur in our saline treated 
groups. Furthermore, there was not a significant difference between IL-1Ra treated animals that 
were re-exposed to the CS and IL-1Ra treated animals that were returned to their home cage (p > 
36 
0.05), indicating that blockade of IL-1 receptor signaling attenuates heroin-conditioned 
immunosuppression of iNOS mRNA. 
Figure 3.2b demonstrates the effect of intra-BLA IL-1 antagonism on LPS-induced 
nitrate/nitrite levels in blood plasma. ANOVA revealed a significant context by treatment 
interaction in the BLA [F(2, 16) = 5.97, p < .05]. In addition, ANOVA revealed a significant 
main effect of re-exposure to the CS [F(1, 16) = 11.09, p < .005] on nitrate/nitrite levels. 
Planned comparisons revealed that saline-treated rats exposed to the heroin-paired context 
exhibited a reduction in nitrate/nitrite levels compared to animals placed in home cages (p < 
0.005). Again, there was not a significant difference between IL-1Ra treated animals that were 
re-exposed to the CS and IL-1Ra treated animals that were returned to their home cage (p > 
0.05), indicating that antagonism of IL-1 receptor signaling attenuates heroin-conditioned 
immunosuppression of nitrate/nitrite production. 
 
Figure 3.2: (A) Effects of BLA IL-1 antagonism on LPS-induced expression of iNOS mRNA as 
determined by real-time RT-PCR. (B) Effects of BLA IL-1 antagonism on LPS-induced 
nitrate/nitrite serum levels as determined by Greiss Reagent Assay. The data are expressed as the 
mean micromolar concentration of nitrite/nitrate. The error bars represent SEM. † p < 0.05 
compared with Home Cage-Saline group. 
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Effects of caudate putamen IL-1 antagonism on heroin-conditioned immunomodulaiton  
Following the discovery that BLA IL-1 signaling mediates heroin-conditioned 
immunosuppression, experiment 2 was conducted to verify that these effects were specific to the 
BLA and not a result of diffusion of IL-1Ra into the CPu, which is located dorsal to the BLA. 
Figure 3.3a shows the effect of CPu IL-1 receptor blockade on LPS-induced iNOS mRNA 
expression. ANOVA revealed no significant context by treatment interaction in the mNAcS 
[F(2,24) = .02, p > 0.05]; however, the ANOVA revealed a significant main effect of re-
exposure to the CS on iNOS mRNA expression [F(1,24) = 16.89, p < 0.001]. Planned 
comparisons revealed that saline-treated rats exposed to the heroin-paired context exhibited a 
reduction in iNOS mRNA expression compared to animals placed in home cages (p < 0.01), 
confirming that our model produced conditioned immunosuppression in saline treated animals. 
Furthermore, IL-1Ra infusion had no effect on iNOS levels in animals re-exposed to the CS 
compared to saline treated animals re-exposed to the CS (p < 0.05), demonstrating that blockade 
of IL-1 receptor signaling does not attenuate heroin-conditioned immunosuppression of iNOS 
mRNA. 
Figure 3.3b illustrates the effect of CPu IL-1 receptor antagonism on LPS-induced levels 
of nitrate/nitrite in blood plasma. One animal was excluded from the following analyses due to 
qualifying as an outlier as determined by Grubbs test. The ANOVA revealed a significant main 
effect of re-exposure to the CS on nitrate/nitrite plasma levels [F(1,23) = 22.98, p < 0.0001] and 
no significant context by treatment interaction [F(2,23) = .02, p > 0.05]. Planned comparisons 
revealed that saline-treated rats exposed to the heroin-paired context exhibited a reduction in 
nitrate/nitrite levels compared to animals placed in home cages (p < 0.005). Importantly, there 
was a significant difference in nitrate/nitrite levels between in IL-1Ra treated animals that were 
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re-exposed to the CS compared to home cage (p < 0.05), indicating that CPu IL-1 does not 
mediate heroin-conditioned immunosuppression of NO production. Thus these data confirm that 
our findings following BLA IL-1Ra administration were not due to diffusion into the CPu. 
 
Figure 3.3: (A) Effects of CPu IL-1 antagonism on LPS-induced expression of iNOS mRNA as 
determined by real-time RT-PCR. (B) Effects of CPu IL-1 antagonism on LPS-induced 
nitrate/nitrite serum levels as determined by Greiss Reagent Assay. The data are expressed as the 
mean micromolar concentration of nitrite/nitrate. The error bars represent SEM. † p < 0.05; *p < 
0.05 compared with appropriate Home Cage control. 
 
 
Effects of medial nucleus accumbens shell IL-1 antagonism on heroin-conditioned 
immunomodulation 
Figure 3.4a depicts the effect of mNAcS IL-1 receptor blockade on LPS-induced iNOS 
mRNA expression. ANOVA revealed no significant context by treatment interaction in the 
mNAcS [F(2,22) = 0.20, p > 0.05]; however, ANOVA revealed a significant main effect of re-
exposure to the CS on iNOS mRNA expression [F(1,22) = 31.93, p < 0.0001]. Planned 
comparisons revealed that saline-treated rats exposed to the heroin-paired context exhibited a 
reduction in iNOS expression compared to animals placed in home cages (p < 0.005). 
Furthermore, IL-1Ra treated animals re-exposed to the CS had significantly lower iNOS levels 
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compared to IL-1Ra treated home cage animals (p < 0.05), indicating that blockade of IL-1 
receptor signaling had no effect on heroin-conditioned immunosuppression of iNOS mRNA. 
Figure 3.4b represents the effect of mNAcS IL-1 receptor antagonism on LPS-induced 
levels of nitrate/nitrite in blood plasma. The ANOVA revealed a significant main effect of re-
exposure to the CS on nitrate/nitrite plasma levels [F(1,22) = 6.80, p < 0.05]  and no significant 
context by treatment interaction [F(2, 22) = 2.09, p > 0.05]. Planned comparisons revealed that 
IL-1Ra did not alter the immunosuppressive effect of the CS compared to home cage treated 
animals (p < 0.05), demonstrating that mNAcS IL-1 does not mediate heroin-conditioned 
immunosuppression of iNOS mRNA expression and NO production. 
 
Figure 3.4: (A) Effects of mNAcS IL-1 antagonism on LPS-induced expression of iNOS mRNA 
as determined by real-time RT-PCR. (B) Effects of mNAcSIL-1 antagonism on LPS-induced 
nitrate/nitrite serum levels as determined by Greiss Reagent Assay. The data are expressed as the 
mean micromolar concentration of nitrite/nitrate. The error bars represent SEM. † p < 0.05; *p < 
0.05 compared with appropriate Home Cage control. 
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Discussion 
 It is well established that re-exposure to a previously heroin-paired context results in 
immunosuppressive effects that are similar to heroin administration alone. The studies presented 
in the current chapter indicate that blockade of IL-1 receptor signaling in the BLA, but not the 
mNAcS or CPu, mediates the immunosuppressive effects of a heroin-paired context on iNOS 
mRNA expression and NO production. These studies are the first to identify BLA IL-1 as an 
important mediator in the expression of learned associations and, specifically, heroin-conditioned 
immunosuppression.  
The mechanisms by which IL-1 mediates the expression of heroin-conditioned 
immunosuppression are unknown. One potential contributor to this effect is microglial cell 
activation. It is understood that the primary source of IL-1β in the brain is glial cells. Microglia 
indirectly modulate neuronal transmission via the release of astroglial modulators, which 
subsequently act upon neighboring astrocytes. A wealth of evidence has accumulated indicating 
that microglia synthesize and release neuro- and glialmodulators, such as IL-1, which has been 
shown to be critical mediators of neurotransmission. For instance, in vitro IL-1β application 
produces electrophysiological changes in various brain regions, such as modulation of inhibitory 
transmission in the hippocampus (Zeise et al., 1992, Zeise et al., 1997, Wang et al., 2000), 
amygdala (Yu and Shinnick-Gallagher, 1994, Bajo et al., 2015), cortex (Miller and Fahey, 1994, 
Miller et al., 1991, Pringle et al., 1996), and hypothalamus (Feleder et al., 1998). In addition, IL-
1β affects excitatory transmission in the cortex (Miller and Fahey, 1994), hippocampus 
(Bellinger et al., 1993, Cunningham et al., 1996, Coogan and O'Connor, 1997, Luk et al., 1999), 
and amygdala (Yu and Shinnick-Gallagher, 1994).  Based on the regions of interest and 
experimental procedures used in these studies, it appears that IL-1 receptor activation modulates 
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neurotransmission in a site-specific and concentration-dependent manner. Thus, it is clear that 
the role of IL-1 signaling is complex and requires further study to elucidate the mechanisms and 
conditions under which IL-1 exerts its physiologic and pathophysiologic effects. 
The observation that BLA IL-1 is important for the expression of heroin-conditioned 
immunosuppression further supports the significance of IL-1 signaling in models of learning and 
memory. Surprisingly, there is a dearth of studies investigating the effect of BLA IL-1 in these 
models. However, there has been extensive research conducted investigating IL-1 within the 
hippocampus and its role in cognitive function. Findings indicate that IL-1 is important for 
memory consolidation and the induction of LTP (Schneider et al., 1998, O'Connor and Coogan, 
1999, Coogan et al., 1999). In addition, inhibition of IL-1 signaling by genetic or 
pharmacological means results in learning and/or memory impairments. For example, a study 
conducted in our laboratory found that inhibition of IL-1β mRNA expression in the dorsal 
hippocampus prior to re-exposure to a previously heroin-paired context attenuated the 
conditioned immunosuppressive effect on NO production and iNOS mRNA expression, 
indicating that IL-1β is an important mediator in heroin-conditioned immunosuppression 
(Szczytkowski et al., 2013). 
The lack of an effect of mNAcS IL-1 receptor antagonism is somewhat surprising. The 
dense IL-1β immunoreactivity in the mNAcS reported in Chapter 1 is indicative of microglia 
activity, which induces IL-1β expression. In addition, a previous study reported significant 
microglial activation following morphine CPP (Zhang et al., 2012), suggesting that 
glialmodulators could play a role in drug-context associative learning. Furthermore, a study in 
our laboratory demonstrated that antagonism of dopamine in the mNAcS blocks heroin-
conditioned immunosuppression. Interestingly, Song and colleagues (1998) suggested that IL-1β 
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may modulate dopamine activity in the NAc. Following IL-1β administration, the typically 
observed decline of the dopamine metabolite, dihydroxyphenylacetic acid, in saline treated 
animals was prevented, suggesting an increase in dopamine release. However, it’s unknown 
whether this effect was due to inefficient metabolite clearance or increased dopamine levels. 
Nevertheless, BLA IL-1 signaling could potentially modulate NAc dopamine, as stimulation of 
BLA glutamatergic efferents to the NAc have been shown to result in dopamine release 
(Floresco et al., 1998). Further studies are needed in order to elucidate the cell types and 
mechanisms by which IL-1 mediates these conditioned effects. In addition, a larger dose of IL-
1Ra may prove to result in the suppression of other proinflammatory mediators in addition to NO 
production and iNOS mRNA expression.  
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 CHAPTER 4 
THE ROLE OF BASOLATERAL AMYGDALA INTERLEUKIN-1β SIGNALING IN THE 
INDUCTION OF PERIPHERAL IMMUNOSUPPRESSION 
Introduction 
The studies discussed in Chapter 3 indicate that IL-1β signaling in the BLA is necessary 
for the expression of heroin-conditioned immunosuppression of NO production and iNOS 
expression. While I demonstrated that these effects are due to re-exposure to the heroin-paired 
context, it is unknown whether IL-1β signaling alone in the BLA can induce peripheral immune 
alterations. Therefore, the current study sought to determine the effects of BLA recombinant rat 
IL-1β (rrIL-1β) administration on the production of NO and expression of iNOS.  
Interestingly, centrally administered IL-1β has been shown to modulate peripheral 
immune function. For instance, i.c.v. IL-1β administration produced a reduction in NK cell 
activity and IL-2 production in blood and spleen tissue. These effects were not observed 
following peripheral IL-1β administration, suggesting centrally active IL-1β is important for the 
induction of peripheral immunosuppression (Sundar et al., 1989). These findings indicate that 
IL-b mediates peripheral immunosuppression, but the mechanisms mediating this effect have not 
been well characterized. 
As discussed in Chapter 3, IL-1β has been shown to produce many electrophysiological 
changes in vitro. In addition, IL-1β modulates neurotransmitter release in various brain regions 
in vivo. For example, i.c.v. infusions of IL-1β decrease norepinephrine in the amygdala and 
44 
hippocampus, increase serotonin in the amygdala, and increase dopamine in the midbrain, 
hippocampus and amygdala (Song et al., 2006). Furthermore, IL-1β potentiates the release of 
dopamine, norepinephrine and serotonin in the hypothalamus (Mohankumar et al., 1991, 
Shintani et al., 1993, Deleplanque et al., 1994). These data indicate that IL-1β signaling has 
widespread effects on neurobiolgoical function.  
IL-1β’s effects on dopamine are of particular interest to the current line of research. 
Dopamine signaling has been previously shown to mediate peripheral immunosuppression. 
Lesioning of nigrostriatal and mesolimbic dopaminergic neurons impairs lymphocyte 
proliferation and NK cell activity (Deleplanque et al., 1994).  Moreover, stimulation of dopamine 
D1 receptors in the nucleus accumbens and hippocampus has been shown to reduce splenic 
lymphocyte proliferation (Nistico et al., 1994). Furthermore, previous studies in our laboratory 
have demonstrated that morphine and heroin’s immunosuppressive effects are mediated by 
central dopamine signaling. Pharmacological blockade of dopamine D1 receptors in the mNAcS 
attenuated the immunosuppressive effect of heroin and morphine on NK cell activity and iNOS 
expression, whereas stimulation of mNAcS D1 receptors produced reductions in NK cell activity 
similar to opioid administration alone (Saurer et al., 2004). Evidence demonstrating that 
stimulation of BLA glutamatergic efferents increases dopamine release in the NAc suggests that 
BLA neurotransmission can modulate NAc dopamine (Floresco et al., 1998). Thus, given IL-
1β’s ability to modulate amygdalar dopamine (Song et al., 2006), astrocytes (Jing et al., 2010), it 
is possible that IL-1β modulates BLA efferent synaptic transmission of dopamine. In theory, 
BLA IL-1β could produce an immunosuppressive effect similar to opiate administration. 
Little is known about the effect IL-1β signaling in the BLA. Exogenous application of IL-
1β to brain slices has been shown to modulate excitatory and inhibitory BLA neurotransmission. 
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These effects appear to mediated by presynaptic mechanisms, as IL-1β application inhibited both 
excitatory and inhibitory postsynaptic potentials (EPSPs/IPSPs) induced by stimulation of stria 
terminalis or lateral amygdala afferents but not GABA or glutamate receptor postsynaptic actions  
within the BLA (Yu and Shinnick-Gallagher, 1994). It is unknown how these effects influence 
BLA efferent signaling mediated by other projections to the BLA, such as dopaminergic 
projections from the VTA. These BLA dopaminergic afferents could produce inhibitory or 
excitatory signaling or both depending on the region receiving BLA projections and cell type 
being modulated by IL-1β. This possibility is supported by findings from Yu and colleagues 
(1994) based on the observation that EPSP amplitude was increased in some neurons despite IL-
1β-induced inhibition, suggesting that disinhibition may result in certain neuronal populations. 
Disinhibition of BLA neurons, such as glutamatergic efferents projecting to the mNAcS, could 
affect neurotransmitters known to mediate peripheral immunosuppression, such as dopamine 
(Saurer et al., 2004). In order to test this hypothesis, NO production and iNOS mRNA expression 
were assessed in animals receiving intra-BLA infusions of various doses of rrIL-1β. 
Materials and Methods 
Animals 
Male Lewis rats, weighing 225–250 g, were purchased from Charles River Laboratories 
(Raleigh, NC, USA). Upon arrival, animals were housed individually in plastic cages in a colony 
room with a reversed light-dark (12-h) cycle maintained through artificial illumination. Animals 
were allowed access to food and water ad libitum throughout the experiment except for the time 
spent in the conditioning chambers when food and water were not available. All animals were 
given a 2-week habituation period before the start of experimental manipulations and were 
handled regularly during this time. All procedures described were approved by the IACUC of the 
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University of North Carolina at Chapel Hill and conformed to NIH guidelines on the care and 
use of laboratory animals. 
Surgical Procedures 
Animals were fully anesthetized with 0.35 mL intramuscular injections of 1:1 (vol:vol) 
ketamine hydrochloride (100 mg/mL) mixed with xylazine (20 mg/mL) and placed into the 
stereotaxic apparatus. Animals were implanted bilaterally with 26-gauge guide cannulae (Plastics 
One, Roanoke, VA, USA). The cannulae were directed towards the BLA (AP −2.5, ML ± 5.0, 
DV −6.6 mm, relative to bregma). Animals were given a 2-week post-surgical recovery period 
before experimentation began.  
Test of Recombinant IL-1β-induced Peripheral Immunosuppression 
One week following surgery animals received bilateral site-specific microinfusions of 0, 
1, 10, or 100ng of recombinant rat IL-1β (0.5 μl per hemisphere). Injectors extended 2 mm 
beyond the tip of the guide cannula. Injections were delivered over 2 min, and the injectors were 
left in place for 1 min after the injection to allow for proper diffusion of fluid away from the 
infusion site. Thirty minutes following microinfusions all rats received a subcutaneous injection 
of LPS (1,000 μg/kg) and were immediately returned to their home cages. LPS, a component of 
the cell wall of Gram negative bacteria, was used to induce iNOS production. Six hours after 
LPS administration, all animals were euthanized.  The 6-h time point was selected based on 
previous research in our laboratory showing maximal iNOS induction 6 h following LPS 
administration (Lysle and How, 2000). 
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Histology 
Samples of spleen and blood were collected for analysis. Spleen samples were either 
stored in an Ambion® RNA Later solution or Roche complete protease inhibitor cocktail 
solution. To confirm proper cannula placement, Alcian blue dye was infused via the cannula. 
Brains were then extracted and flash frozen and at − 80 °C until further analysis. Coronal 
sections (40 μm) were taken and stained with cresyl violet for verification of cannula placement. 
The data of animals with cannula placement outside of the targeted region were removed from 
subsequent data analyses. 
                                         
Figure 4.1: Illustration of verified cannula placement. Black dots represent the ventral most 
point of injector in the BLA. 
Real-Time RT-PCR 
Tissue was processed by the UNC Animal Clinical Chemistry and Gene Expression 
Laboratories according to protocols previously reported (Kim et al, 2002). In brief, spleen tissue 
(50-100 mg) was homogenized in RNA lysis buffer (PE Biosystems, Foster City, CA) with Ca2 
and Mg2- free PB using a Fast Prep 120 mixer (QBIOgene, Vista, CA). RNA isolations were 
AP +2.04 
 
AP +2.28 
 
AP +2.52 
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purified using the ABI Prism 6700 automated nucleic acid workstation (PE Biosystems) 
according to the manufacturer’s protocol. Real-time RT-PCR amplifications were performed in 
the ABI Prism 7700 sequence detector (PE Biosystems) in a total volume of 30 μl (10 μl RNA 
plus 20 μl reaction mixture). Each RT-PCR amplification was performed in duplicate: 30 min at 
48°C for the RT reaction and 10 min at 94°C followed by 40 temperature cycles (15 s at 94°C 
and 1 min at 60°C). Copy numbers were measured using the Sequence Detector Software in the 
ABI Prism 770 Sequence Detector System. Signal intensity was normalized to 18S as an 
endogenous control. The nucleotide sequences of the PCR primers and fluorogenic probes used 
for the iNOS and 18S genes were as follows: iNOS forward: 5’-AGCGGC TCC ATGACTCTC 
A-3’, reverse:   5’-TGC CTGCACCCAAACACCAA-3’, probe: 5’-
FTCATGCGGCCTCCTTTGAGCCCTCQ-3’; 18S: forward: 5’-
AGAAACGGCTACCACATCCA-3’, reverse: 5’-CTCGAAAGAGTCCTGTATTGT-3’, probe: 
5’-FAGGCAGCAGGCGCGCAAATTACQ. 
Nitrite/Nitrate Assay  
The nitrite/nitrate concentration in plasma samples was assessed using the Greiss reagent 
assay described previously (Szczytkowski and Lysle, 2007). Briefly, 6 μl of plasma was diluted 
in 44 μl of dH2O, and the sample was incubated in the dark for 90 min with 10 μl of nitrate 
reductase (1.0 U/ml), 20 μl of 0.31M phosphate buffer (pH 7.5), 10 μl of 0.86mM NADPH 
(Sigma), and 10 μl of 0.11mM flavin adenine dinucleotide in individual wells of a 96-well plate. 
Next, 200 ml of Greiss reagent, consisting of a 1:1 (v/v) solution 1% sulfanilamide in 5.0% 
phosphoric acid and 0.1% N-(1-napthyl) ethyl-enedamine dihydrochloride in distilled water, was 
added to the samples. The color was allowed to develop for 10 min at room temperature, after 
which, the absorbance was determined using a spectrophotometer set at 550 nm. All reactions 
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were carried out in triplicate. The total micromolar concentration of nitrite was determined for 
each sample based on a standard curve. Recovery of nitrate is greater than 95% using this assay. 
Statistical Analysis 
One-way analysis of variance was performed on iNOS mRNA expression and 
nitrate/nitrite levels. All analyses were performed with statistical significance set at p < .05. 
Results 
Effects of intra-basolateral amygdala recombinant rat IL-1β administration 
Figure 4.2 shows the effect of intra-BLA administration of rrIL-1β on LPS-induced iNOS 
mRNA expression following re-exposure to the heroin-paired context or home cage. ANOVA 
revealed no significant differences between groups receiving different doses or rrIL-1β [F(3,21) 
= 2.47, p > 0.05]. Similarly, figure 4.3 illustrates the effect of intra-BLA administration of rrIL-
1β on LPS-induced nitrate/nitrite production in blood plasma. Again, ANOVA revealed no 
significant differences between groups across various doses [F(3,21) = 2.03, p > 0.05]. Taken 
together, these data suggest that intra-BLA rrIL-1β administration does not alter peripheral 
immune function at the doses tested. 
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Figure 4.2: Effects of BLA recombinant rat IL-1β on LPS-induced iNOS mRNA as determined 
by Greiss Reagent Assay. The data are expressed as the mean micromolar concentration of 
nitrite/nitrate. The error bars represent SEM. 
 
  
Figure 4.3: Effects of BLA recombinant rat IL-1β on LPS-induced expression of nitrate/nitrite 
serum levels as determined by real-time RT-PCR. The data are expressed as the mean 
micromolar concentration of nitrite/nitrate. The error bars represent SEM.  
 
Discussion 
The study presented in the current chapter investigated the role of BLA IL-1β signaling in 
the modulation of peripheral immune alterations. Animals received intra-BLA administration of 
various doses of rrIL-1β in order to determine if IL-1β expression in the BLA is capable of 
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modulating NO production and iNOS expression following an immunologic challenge. Our 
findings indicate that intra-BLA administration of IL-1β has no effect on iNOS mRNA 
expression or NO production. 
It is well established that IL-1β   plays a role in learning and memory (Schneider et al., 
1998, Goshen et al., 2007, Yirmiya et al., 2002). However, the role of IL-1β signaling is 
complex, producing diverse and even opposing effects on synaptic transmission in different CNS 
tissue. For example, IL-1β has been shown to enhance the frequency and amplitude of excitatory 
post synaptic currents in the spinal cord, indicating that it can potentiate synaptic transmission 
(Kawasaki et al., 2008), whereas certain levels of IL-1β expression blocks LTP in the 
hippocampus in vitro (Katsuki et al., 1990, Bellinger et al., 1993, Cunningham et al., 1996) and 
in vivo (Murray and Lynch, 1998, O'Connor and Coogan, 1999)  rather than facilitating 
glutamatergic synaptic transmission. Furthermore, in vitro evidence suggests that IL-1β has vast 
effects on mechanisms that modulate LTP, such as inhibition of hippocampal calcium (Ca2
+)
 
influx and glutamate release (Murray and Lynch, 1998) and  increased chloride transport and 
inhibition of Ca2
+
 increases in cortical synaptosomes (Miller and Fahey, 1994).  These 
contradictory and region-specific findings remain to be understood in regards to how IL-1β 
modulates synaptic transmission in CNS tissue. Thus, it is difficult to speculate on how IL-1β   
may be acting in the BLA. However, based on these previous studies, it’s possible that 
exogenous intra-BLA administration acts to inhibit BLA excitatory signaling, thus inhibiting, 
instead of stimulating, neurotransmitter release in BLA-projecting regions, such as the mNAcS. 
If this is, in fact, what is taking place, it would be interesting to investigate the role of intra-BLA 
IL-1β administration in the expression of heroin-conditioned immunosuppression. Functional 
inactivation of the BLA using a GABA agonist cocktail has been shown to block heroin-
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conditioned immunosuppression (Szczytkowski and Lysle, 2008); therefore, I would expect to 
see a similar effect following exogenous IL-1β administration.  
It is also possible that intra-BLA IL-1β administration did produce suppression of the 
peripheral immune response, but due to the doses of IL-1β used this effect could have been 
washed out. IL-1β has been shown to induce the expression of iNOS and production of nitric 
oxide. In addition, IL-1β has been reported to damage the blood-brain barrier, which could cause 
IL-1β to leak into the bloodstream and migrate to peripheral organs, such as the spleen. This 
leakage into the periphery could then stimulate the expression of iNOS and production of NO, 
causing levels to return to those normally observed in control animals. Further studies are needed 
to investigate whether these doses of IL-1β do indeed affect blood-brain barrier permeability in 
the BLA. If IL-1β is affecting blood-brain barrier integrity, a lower dose range of IL-1β would be 
needed to explore the effects of IL-1β-induced peripheral immunosuppression. Finally, it would 
be interesting to characterize the role IL-1β in the VTA and mNAcS, as IL-1β’s inhibitory 
effects could result in disinhibition of VTA dopaminergic projections and modulate dopamine 
release in the mNAcS. 
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CHAPTER 5 
GENERAL DISCUSSION 
Experimental Findings 
 The studies presented in this dissertation offer novel insights into a neurobiological 
mechanism mediating the conditioned immunosuppressive effects of heroin. Over the past two 
decades research has discovered the involvement of many traditional neuromodulators 
responsible for the immunosuppressive effects of opiates, with some these neuromodulators also 
being necessary for the expression of heroin-conditioned immunosuppression. However, the 
current studies investigated the importance of a non-traditional neuromodulator, IL-1, in our 
established model of heroin-conditioned immunosuppression. Several lines of research have 
begun to characterize the role of IL-1 signaling in normal and pathological biological function, 
including learning and memory, but the mechanisms mediating IL-1-induced memory 
impairments are poorly understood. Thus, the studies presented in this dissertation sought to 
offer insight into a novel mechanism mediating heroin-conditioned immunomodulation.  
Chapters 2 and 3 discuss experiments exploring the role of IL-1 in a model of heroin-
conditioned immunosuppression. Our laboratory has demonstrated that repeatedly pairing an 
immune altering stimulus (e.g. heroin) with a neutral stimulus causes the previously neutral 
stimulus to elicit immune altering effects per se. Subsequently, numerous studies were conducted 
investigating the neural circuit mediating this phenomenon.  For example, the functional integrity 
of the VTA, BLA, mNAcS and dorsal hippocampus have been demonstrated to be necessary for 
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the expression of heroin-conditioned immunosuppression (Szczytkowski et al., 2011, 
Szczytkowski et al., 2013, Szczytkowski and Lysle, 2008, Saurer et al., 2008a, Hutson et al., 
2014). In addition, our laboratory demonstrated that blockade of dopamine D1 receptors in the 
BLA and mNAcS prior to re-exposure to a previously drug-paired context results in the 
attenuation of heroin-conditioned immune suppression of various immune parameters (Saurer et 
al., 2008a, Szczytkowski and Lysle, 2010). Thus, these studies identified several mesolimbic 
neural substrates important in the expression of our conditioned effects. 
Previous research into the neurobiological mechanisms of IL-1 signaling has offered 
valuable insights into its potential effects on neural processing. Interestingly, i.c.v. IL-1β 
administration altered dopamine concentrations in the amygdala (Song et al., 2006), suggesting 
that IL-1β signaling could play a role in dopamine transmission.  In addition, IL-1 has been 
shown to have a critical role in neural plasticity, learning and memory. For instance, IL-1β 
mRNA expression is elevated following fear conditioning (Goshen et al., 2007) and is necessary 
for the induction and maintenance of LTP, as blockade of IL-1 signaling attenuated LTP 
(Schmid et al., 2009). Moreover, blockade of IL-1 signaling impaired memory of passive 
avoidance behavior and contextual fear conditioning (Yirmiya et al., 2002, Goshen et al., 2007). 
Lastly, genetic deletion of IL-1 receptors and IL-1Ra disrupted learning in a spatial memory 
paradigm (Avital et al., 2003). In contrast to these findings, excessive IL-1β expression also 
results in memory impairments. Bath application of IL-1β has been shown to inhibit LTP in 
hippocampal slices. In addition, IL-1β administration prior to exposure to a spatial water maze 
task impaired memory (Oitzl et al., 1993). Furthermore, IL-1β infused into the ventricles or 
dorsal hippocampus following fear conditioning resulted in impaired contextual memory 
(Goshen et al., 2007, Jones et al., 2015). Taken together, it is evident that basal levels of IL-1 are 
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necessary for normal physiologic function and deviation from these levels results in deficits in 
learning and memory. Based on these findings, the current studies sought to determine whether 
BLA and mNAcS IL-1 signaling was necessary for the expression of heroin-conditioned 
immunosuppression.  
As discussed in Chapter 2, prior to studying the role of IL-1 in heroin-conditioned 
immunomodulation, I performed an experiment to verify the presence of IL-1β in the BLA and 
mNAcS. In addition, I aimed to determine the time course of IL-1β expression following re-
exposure to a heroin-paired context. Animals received five conditioning sessions, with each 
session separated by 48-hrs, where 1 mg/kg heroin was administered immediately prior to 
placement into a distinct context. Six days after the final conditioning session, rats were 
sacrificed following a 0, 15, 60 or 120 min (re-exposure for 60 minutes then returned to home 
cage for 60 min) re-exposure to the heroin-paired context. Immunohistochemical analysis of IL-
1β immunoreactivity in the BLA and mNAcS revealed that IL-1β is expressed at all time points 
and at similar levels, indicating that IL-1 signaling is active within these brain regions six days 
following heroin conditioning. These findings are in line with previous reports indicating dense 
IL-1 receptor expression in the BLA (Konsman et al., 2000, Yabuuchi et al., 1994b). I 
hypothesized that IL-1β expression would be elevated as a result of re-exposure to a heroin-
paired context based on findings demonstrating increased microglia activation following re-
exposure to a morphine-paired context in a model of CPP (Schwarz et al., 2011). Therefore, it is 
possible that re-exposure to a heroin-paired context stimulates microglial activation and results in 
subsequent increased IL-1β expression. However, based on our findings, it does not appear that 
BLA or mNAcS IL-1β levels were increased following re-exposure to the heroin-paired context.  
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It is well documented that opiate administration activates microglial cells (Milligan and 
Watkins, 2009). Thus, it is possible that this activated state could persist long after morphine 
exposure. In fact, persistent microglial activation was found five days following morphine 
administration in a model of CPP (Zhang et al., 2012), indicating that microglial activation on 
test day in the studies discussed in this dissertation is possible, as brain tissue was collected at a 
similar time point. Consequently, the lack of differences in IL-1β levels in the BLA and mNAcS 
could be due to persistent microglia activity resulting from heroin conditioning. In order to 
determine whether IL-1β levels were elevated above those of naïve animals, control studies are 
needed to determine if repeated administration of heroin and/or exposure to the conditioned 
stimulus alone results in on long-term microglial activity. 
 The series of experiments conducted in chapter 3 investigated the role of IL-1 signaling 
in heroin-conditioned immunomodulation. As previously discussed, our laboratory has identified 
the BLA and mNAcS as important neural substrates mediating the expression of this conditioned 
effect. Interestingly, morphine-associated contexts have been shown to induce microglial 
activation upon re-exposure to the drug-paired context (Schwarz et al., 2011). Moreover, NFĸ-b 
expression, which is a pathway responsible for IL-1β production and release in glial cells, is 
necessary for the acquisition of morphine CPP (Zhang et al., 2011). Taken together, these 
findings demonstrate that mechanisms involved in IL-1β release are important for associative 
learning. Therefore, to test the hypothesis that IL-1 signaling in the BLA and mNAcS mediates 
heroin-conditioned immunosuppression, animals underwent the same conditioning regimen 
discussed above. At least six days following the final conditioning session, animals received 
bilateral microinfusions of saline vehicle or IL-1Ra into the BLA or mNAcS and then returned to 
their home cage or re-exposed to the previously heroin-paired context for 60 minutes. Following 
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re-exposure, animals were then administered a subcutaneous injection of LPS to induce the 
immune response. Six hours later brain, blood plasma and spleen tissue were collected from each 
subject. Interestingly, blockade of IL-1signaling with IL-1Ra in the BLA, but not mNAcS or 
CPu, attenuated the immunosuppressive effects of the heroin-paired context on NO production 
and iNOS expression. These findings demonstrate for the first time that IL-1 signaling in the 
BLA is necessary for the expression of heroin-conditioned immunosuppression. In fact, to my 
knowledge, this is the first study to demonstrate that BLA IL-1 is an important mechanism 
mediating the expression of any conditioned response.   Our laboratory previously found similar 
results by inhibiting IL-1β mRNA expression in the dorsal hippocampus, indicating that IL-1-
mediated expression of heroin-conditioned immunosuppression is not limited to the BLA. 
Based on the findings presented in Chapter 3 demonstrating that blockade of BLA IL-1 
receptors attenuated the expression of heroin-conditioned immunomodulation, I wanted to 
determine if BLA IL-1β signaling could modulate the induction of peripheral 
immunosuppression. Interestingly, i.c.v. IL-1β administration has been previously shown to 
suppress the peripheral immune response (Sundar et al., 1989). Therefore, I investigated the 
immunomodulatory role of BLA IL-1β signaling alone in response to an immune challenge.  Our 
findings show that various doses of rrIL-1β administration do not suppress peripheral NO 
production or iNOS mRNA expression. These findings oppose what Sundar and colleagues 
(1989) observed, although different proinflammatory mediators were measured. This difference 
could be due to several factors. First, it is unknown which brain region(s) mediate the peripheral 
immunosuppessive effect of i.c.v. IL-1β. One possibility is the hypothalamus, which has been 
shown to increase IL-1 receptor expression following immune challenge (Ilyin et al., 1998) and 
modulate NK cell activity and lymphocyte proliferation via vagal nerve stimulation (Okamoto et 
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al., 1996). In addition, IL-1β stimulates the release of corticotropin releasing hormone 
(Berkenbosch et al., 1987, Sapolsky et al., 1987), which is a critical mediator of the stress 
response. Our laboratory has demonstrated that stimulation of the stress response via the 
hypothalamic-adrenal-pituitary axis suppresses NK cell activity, indicating that activation of the 
stress pathway can result in peripheral immunosuppression (Perez and Lysle, 1995). Lastly, 
excessive IL-1β expression can cause damage to the blood-brain barrier, which could have 
provided a means for BLA-infused rrIL-1β to leak into the bloodstream and migrate to peripheral 
organs (Quagliarello et al., 1991). Thus, if intra-BLA IL-1β infusion reduced NO production or 
iNOS mRNA expression, these levels could have returned to those of control animals due to the 
fact that IL-1β stimulates the production of NO in the periphery. 
 
Potential Mechanisms 
Neuro-Glial Communication 
While much is unknown about the mechanisms by which central IL-1 modulates 
neurotransmission, recent studies have offered a great deal of insight into the complex signaling 
processes that occur during synaptic transmission. Since IL-1β is synthesized and released 
primarily from glial cells, there is an ongoing effort to characterize the role that glia play in IL-1 
signaling. Interestingly, there appears to be little evidence of direct effects of microglia on 
neurotransmission. Thus, it is likely that the neuromodulatory role of microglia-released 
molecules is mediated via astrocytic activation.  
Gliotransmission is defined as the release of gliotransmitters by astrocytes, which include 
D-serine, IL-1β, TNF-α, glutamate, adenosine triphosphate (ATP), lactate, among others. These 
gliotransmitters act to modulate neuronal transmission and plasticity via activation of Gq GPCRs 
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and subsequent increases in Ca2
+
 levels. However, it is unclear whether Ca2
+
 release alone is 
sufficient to modulate neural processing, as studies have reported that inhibition of Ca2
+
 in 
astrocytes has no effect on synaptic activity
 
(Fiacco et al., 2007, Petravicz et al., 2008, Agulhon 
et al., 2010). Recently, proinflammatory mediators have been implicated as playing a critical role 
in astrocyte-mediated neuronal activation. Evidence suggests that activated microglia release 
proinflammatory cytokines, which then activate astrocytes and induce glutamate release (Bezzi 
et al., 2001). Thus, proinflammatory cytokines may act in concert with basal Ca2+ signaling to 
modulate neuronal excitability.  
IL-1 has been identified as a critical mediator of microglia-induced astrocyte activation, 
as central IL-1 administration causes an upregulation of glial fibrillary acidic protein (GFAP), 
which is a marker of astrocyte activation (Balasingam et al., 1994; Lee et al., 2010). IL-1 has 
also been reported to upregulate the proinflammatory cytokines IL-6 and TNF-α (John et al., 
2004). Conversely, blockade of IL-1 signaling inhibits microglia-induced TNF-α release (Basu et 
al., 2002), indicating that IL-1 modulates microglia-derived proinflammatory cytokine release. In 
addition, IL-1 dose-dependently attenuates astrocytic glutamate uptake, which results in 
excessive synaptic activity (Jing et al., 2010). These molecules subsequently induce astrocytic 
activation and, in turn, further release proinflammatory cytokines in an autocrine/paracrine 
fashion, which directly modulate neuronal activity. 
One study recently demonstrated that LPS-induced microglial activation increased 
hippocampal excitatory synaptic transmission.  This effect was found to involve microglia-
initiated activation of metabotropic P2Y purinoceptor 1(P2Y1) receptors on astrocytes, which 
then stimulated the release of glutamate from astrocytes to modulate synaptic metabotropic 
glutamate receptors (Pascual et al., 2012). Interestingly, ATP-induced P2Y1 receptor activation 
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of astrocytes can also increase TNF-α, which has been reported to play a role in neural plasticity 
and learning (Beattie et al., 2002).  These increases in TNF-α subsequently produced elevated 
glutamate release (Domercq et al., 2006, Santello et al., 2011). Taken together, evidence suggests 
that IL-1 activates microglial cells and may initiate microglia-astrocyte communication via 
autocrine/paracrine signaling pathways, resulting in the initiation and enhancement of 
intercellular astrocytic Ca2
+
 signaling and subsequent facilitation of increased neuronal 
excitation.  
TLR4-Dependent Activation of Microglia 
A potential mechanism mediating BLA IL-1 signaling is the TLR4 receptor. Of the 12 
members of the TLR family, TLR4 is the most studied subtype. It is activated by LPS and 
endogenous danger signals, such as residual fragments released from stressed or damaged cells 
(Buchanan et al., 2010). TLR4 is composed of accessory proteins (myeloid differentiation 
protein 2 (MD-2) and cluster of differentiation 14 (CD14)) that play an important role in ligand 
recognition and subsequent intracellular events. Activation of TLRs and classical opioid 
receptors are thought to be, at least in part, responsible for microglial activation and subsequent 
IL-1β release (Hutchinson et al., 2010). However, the contribution of classical opioid receptors 
to neuroglial signaling has recently come into question.   
Interestingly, LPS and opioids bind to similar components of the TLR4/CD14/MD-2 
complex. For example, morphine and LPS preferentially bind to the MD-2 accessory protein and 
subsequently induces oligomerization of the TLR4/MD-2 complex thereby inducing a 
proinflammatory response. Blocking MD-2 eliminates morphine-induced increases in 
proinflammatory markers (Wang et al., 2012), whereas upregulation of TLR4 potentiates 
proinflammatory signaling (Holdridge et al., 2007). This effect, however, was not found to 
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involve classical opioid receptor activation, suggesting that morphine-induced neuroimmune 
signaling is mediated exclusively via the TLR4/MD-2 complex (Wang et al., 2012). Recently, 
the TLR4/MD-2 complex was also shown to modulate morphine-induced accumbal dopamine 
release, as antagonism of the TLR4/MD-2 complex decreased dopamine levels in the NAcS 
(Hutchinson et al., 2012). Dopamine is critical for the expression of heroin-conditioned 
immunosuppression. Thus, it’s possible that dopamine levels are modulated via TLR4 in our 
model. The cell-types(s) mediating morphine’s effect on dopamine are unknown; however, it is 
likely the result of glial cell activation based on high levels of TLR4 receptor expression 
observed on glia (Bsibsi et al., 2002, Holm et al., 2012, Schwarz et al., 2011). Morphine has also 
been shown to increase the activation of microglia and astrocytes. In fact, this effect has been 
observed up to 10 days following the cessation of chronic morphine treatment (Zhang et al., 
2012), suggesting that morphine-induced neuroimmune signaling is not a transient phenomenon. 
Moreover, microglial activation also increases upon re-exposure to a morphine-paired context in 
a model of CPP (Schwarz et al., 2011), further implicating a potential role for IL-1 signaling in 
the expression of conditioned responding. Taken together, these data suggest it is possible that 
IL-1 signaling in the BLA is mediated via TLR4 receptor activation on microglial cells.  
 
Conclusions 
The negative health consequences associated with opioid use have been well 
characterized. Due to the prevalence of opioid use, such as heroin and medicinal opioids, it is 
important to understand the mechanisms that mediate the conditioned effects of opioids on 
immune function. This dissertation provides insight into a novel mechanism mediating heroin-
conditioned immunosuppression and raises many questions that could direct future studies aimed 
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at elucidating other important factors involved in this effect. These studies indicate that 
following heroin-conditioning IL-1β is expressed in the BLA and mNAcS at levels that may be 
indicative of exaggerated neuroimmune signaling. It is important to determine if the schedule of 
heroin administration used in the present studies and/or exposure to a distinct environment can 
induce pathological levels of central IL-1β. In addition, the present findings are the first to 
demonstrate that IL-1 signaling in the BLA is a critical mechanism involved in heroin-
conditioned immunosuppression. Finally, it does not appear that BLA IL-1β signaling is capable 
of inducing peripheral immune suppression in response to an immune challenge. These studies 
further our understanding of the central mechanisms that affect the ability of the immune system 
to respond to infection.  These findings may also provide insight into IL-1-mediated conditioned 
responding in other models of associative learning, potentially leading to novel treatments aimed 
at both drug and non-drug disorders. 
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